Voprosy onkologii
-
In this retrospective clinical study 100 patients with primary unfavorable prognosis stage II Hodgkin lymphoma (HL) (n = 50) or stage IV HL (n = 50). The ABVD chemotherapy allowed to achieve remission in 90% of cases with 5-year relapse-free survival (RFS) and overall survival (OS) of 64% and 92%, the basic BEACOPP regimen lead to the same 90% remission rate with 74% DFS and 94% OS. These results for ABVD and basic BEACOPP regimens are characterized by similar statistic values (p = 1.0; p = 0.6; p = 0.9), although the use basic BEACOPP lead to statically valid decrease of grade III-IV toxicity (p = 0.005). ⋯ HL relapse frequency in ABVD and BEACOPP groups was similar (12% and 8%), there was no statistically valid difference (p = 0.5). In ABVD and basic BEACOPP recipients with stage II/IV HL the primary refractory disease rate was 15%, relapse rate was 10%. Five-year OS in primary refractory and relapsed patients was lower, than in general patient population (64% and 70% compared to 80%), although the difference had no statistical significance (p = 0.6, p = 0.7).
-
Despite of anaesthesiology and intensive care progress in oncology there are some problems that need to be solved. These include low individual significance of perioperative risk scale, the lack of approaches for postoperative correction of risk value, estimation of surgical stress value, approach to detection of pain mechanisms etc. The studies which will resolve these problems allow improving the quality of medical care for cancer patients.
-
Biography Historical Article
[The 85th anniversary of N. N. Petrov Research Institute of Oncology].
-
Clinical Trial
[Use of recombinant factor VIIa to reduce transfusional load in hemorrhaging patients after surgery for malignant tumors].
Often expanded surgical interventions in patients with malignant tumors are accompanied by huge bleeding and require transfusion of big mass of medications prepared from donor blood that may develop different complications. It is showed that with the aim of treatment of hemorrhagic complications the use of recombination factor VIIa allows reducing the surgical blood loss, as well as diminishing hemotransfusional load after surgery especially in patients with malignancies of urogenital system and malignant tumors of the colon and lung.